SCHEMBL17129352

SCHEMBL17129352

CC(C)c1ccc(CC(=O)c2ccc(O)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.67
NPC1 O15118 4/20 0.67
USP5 P45974 1/20 0.53
L3MBTL1 Q9Y468 2/20 0.51
RXRA P19793 1/20 0.49
RXRB P28702 1/20 0.49
NLRP3 Q96P20 1/20 0.48
MAPT P10636 1/20 0.46
ESR1 P03372 3/20 0.46
ESR2 Q92731 3/20 0.46
HSD17B3 P37058 1/20 0.46
CA2 P00918 2/20 0.46
CAMK2A Q9UQM7 1/20 0.46
ESRRG P62508 1/20 0.46
POLB P06746 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
SHBG P04278 1/20 0.45
PTPN1 P18031 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29985938 0.93 USP5 (0.59) RAB9ANPC1USP5L3MBTL1RXRA
SCHEMBL1642242 0.85 NPC1 (0.81) RAB9ANPC1L3MBTL1MAPTESR1
SCHEMBL3917034 0.84 NPC1 (0.56) RAB9ANPC1USP5L3MBTL1RXRA
SCHEMBL17112793 0.82 NPC1 (0.63) RAB9ANPC1RXRARXRBMEN1
SCHEMBL6280928 0.81 USP5 (0.51) RAB9ANPC1USP5L3MBTL1RXRA
SCHEMBL12637601 0.80 NPC1 (0.71) RAB9ANPC1L3MBTL1MAPTESR1
SCHEMBL10649146 0.80 RAB9A (1.00) RAB9ANPC1L3MBTL1MAPTESR1
SCHEMBL12137308 0.80 NPC1 (0.71) RAB9ANPC1L3MBTL1MAPTESR1
SCHEMBL5725840 0.80 RAB9A (1.00) RAB9ANPC1L3MBTL1MAPTESR1
SCHEMBL12835116 0.80 RAB9A (0.72) RAB9ANPC1L3MBTL1MAPTESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10280170-B2 Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as Ros1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2019-05-07 US disclosed
US-20170174690-A1 SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-06-22 US disclosed
US-20170174690-A1 SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-06-22 US disclosed
WO-2015144799-A1 SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2015-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10280170-B2 Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as Ros1 inhibitors ROS1, NOX1, NOX5 RAB9A 682/4885NPC1 835/4885USP5 1511/4885
US-20170174690-A1 SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS ROS1, NOX1, NOX5 RAB9A 682/4885NPC1 835/4885USP5 1511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.